ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,151.59
0.82%
Dow Jones
43,726.80
0.73%
Gold vs US Dollar
2,666.975
0.55%
Brent Oil
73.465
0.86%
Bitcoin
97,168.23
2.98%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Uniqure Nv (0EE0)

  7. Uniqure Nv (0EE0) News

Uniqure Nv (0EE0)

Uniqure Nv
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0EE0
DateTimeSourceHeadlineSymbolCompany
21/11/202412:05UK RegulatoryuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyLSE:0EE0Uniqure Nv
05/11/202412:05UK RegulatoryuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
15/10/202411:05UK RegulatoryuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSLSE:0EE0Uniqure Nv
23/09/202411:05UK RegulatoryuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
15/08/202411:05UK RegulatoryuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
01/08/202411:05UK RegulatoryuniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateLSE:0EE0Uniqure Nv
23/07/202411:05UK RegulatoryuniQure Announces Closing of Sale of Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
09/07/202411:05UK RegulatoryuniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseLSE:0EE0Uniqure Nv
01/07/202411:05UK RegulatoryuniQure Announces Sale of Commercial Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
03/06/202411:05UK RegulatoryuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseLSE:0EE0Uniqure Nv
07/05/202411:05UK RegulatoryuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
28/02/202412:05UK RegulatoryuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
 Showing the most relevant articles for your search:LSE:0EE0

Your Recent History

LSE
POS
Plexus
LSE
DEC
Diversified Energy
LSE
VAST
Vast Resources
LSE
SYME
Supply@me Capital
LSE
LIO
Liontrust Asset Management
LSE
MIN
Minoan
LSE
STX
Shield Therapeutics
LSE
AAZ
Anglo Asian Mining
LSE
ITM
Itm Power
LSE
GGP
Greatland Gold
LSE
BOO
Boohoo
LSE
TERN
Tern
LSE
TW.
Taylor Wimpey
LSE
NEXN
Nexxen
LSE
MTRO
Metro Bank
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06